Patorno, Elisabetta

Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor

Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 334

Lithium Use in Pregnancy and the Risk of Cardiac Malformations

Patorno, E., Huybrechts, K. F., Bateman, B. T., Cohen, J. M., Desai, R. J., Mogun, H., Cohen, L. S., & Hernandez-Diaz, S. (2017) · New England Journal of Medicine

Pregnancy and Medication ImpactPharmacological Effects and Toxicity Studies

Cited by 265

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis From the EMPRISE Study

Patorno, E., Pawar, A., Franklin, J. M., Najafzadeh, M., Déruaz-Luyet, A., Brodovicz, K. G., Sambevski, S., Bessette, L. G., Santiago Ortiz, A. J., Kulldorff, M., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 215

Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy

Cesta, C. E., Rotem, R., Bateman, B. T., Chodick, G., Cohen, J. M., Furu, K., Gissler, M., Huybrechts, K. F., Kjerpeseth, L. J., Leinonen, M. K., et al. (2024) · JAMA Internal Medicine

Pregnancy and Medication ImpactGestational Diabetes Research and Management

Cited by 200

Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease

Patorno, E., Htoo, P. T., Glynn, R. J., Schneeweiss, S., Wexler, D. J., Pawar, A., Bessette, L. G., Chin, K., Everett, B. M., & Kim, S. C. (2021) · Annals of Internal Medicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 103

Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations

Bateman, B. T., Patorno, E., Desai, R. J., Seely, E. W., Mogun, H., Dejene, S. Z., Fischer, M. A., Friedman, A. M., Hernandez-Diaz, S., & Huybrechts, K. F. (2017) · Obstetrics & Gynecology

Pregnancy and Medication ImpactPharmacological Effects and Toxicity Studies

Cited by 102

Glucagon-like peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes

Simon, T. G., Patorno, E., & Schneeweiss, S. (2022) · Clinical Gastroenterology and Hepatology

Diabetes Treatment and ManagementLiver Disease and Transplantation

Cited by 98

Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018.

Dave, C. V., Schneeweiss, S., Wexler, D. J., Brill, G., & Patorno, E. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 97

Validation of obesity‐related diagnosis codes in claims data

Suissa, K., Schneeweiss, S., Lin, K. J., Brill, G., Kim, S. C., & Patorno, E. (2021) · Diabetes, Obesity and Metabolism

Medical Coding and Health InformationObesity, Physical Activity, Diet

Cited by 89

Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study

Fralick, M., Kim, S. C., Schneeweiss, S., Everett, B. M., Glynn, R. J., & Patorno, E. (2020) · BMJ

Diabetes Treatment and ManagementDiabetic Foot Ulcer Assessment and Management

Cited by 63

Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study

Alkabbani, W., Suissa, K., Gu, K. D., Cromer, S. J., Paik, J. M., Bykov, K., Hobai, I., Thompson, C. C., Wexler, D. J., & Patorno, E. (2024) · BMJ

Diabetes Treatment and ManagementAirway Management and Intubation Techniques

Cited by 60

Association of sodium-glucose cotransporter 2 inhibitor treatment with risk of hospitalization for Fournier gangrene among men

Dave, C. V., Schneeweiss, S., & Patorno, E. (2019) · JAMA Internal Medicine

Diabetes Treatment and ManagementStreptococcal Infections and Treatments

Cited by 44

Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States

Suissa, K., Schneeweiss, S., Kim, D. W., & Patorno, E. (2021) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 41

Contemporary trends in the utilization of second‐line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom

Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., Azoulay, L., & Patorno, E. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 39

Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure

Cromer, S. J., Lauffenburger, J. C., Levin, R., & Patorno, E. (2023) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 36

Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries

Hawley, C. E., Lauffenburger, J. C., Paik, J. M., Wexler, D. J., Kim, S. C., & Patorno, E. (2022) · Diabetes Care

Medication Adherence and ComplianceDiabetes Treatment and Management

Cited by 22

Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019

Wang, E., Patorno, E., Khosrow-Khavar, F., Crystal, S., & Dave, C. V. (2025) · Diabetologia

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 14

GLP-1 Receptor Agonists and Gastrointestinal Adverse Events

Suissa, K., Cromer, S. J., & Patorno, E. (2024) · JAMA

Diabetes Treatment and ManagementPharmacovigilance and Adverse Drug Reactions

Cited by 12

223-OR: Emulation of the Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT)

OSTROMINSKI, J., ORTEGA-MONTIEL, J., TESFAYE, H., ALIX, C., WEXLER, D. J., PAIK, J. M., & PATORNO, E. (2025) · Diabetes

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3